Department of Medicine, University of California, San Francisco, California; Medical Service, Veterans Affairs Health Care System, San Francisco, California.
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
J Heart Lung Transplant. 2024 Nov;43(11):1820-1832. doi: 10.1016/j.healun.2024.07.010. Epub 2024 Jul 24.
Chronic lung allograft dysfunction (CLAD) limits survival following lung transplant, but substantial lung damage occurs before diagnosis by traditional methods. We hypothesized that small airway gene expression patterns could identify CLAD risk before spirometric diagnosis and predict subsequent graft failure.
Candidate genes from 4 rejection-associated transcript sets were assessed for associations with CLAD or graft failure in a derivation cohort of 156 small airway brushes from 45 CLAD cases and 37 time-matched controls with >1-year stable lung function. Candidate genes not associated with CLAD and time to graft failure were excluded, yielding the Airway Inflammation 2 (AI2) gene set. Area under the receiver operating curve (AUC) for CLAD and competing risks of death or graft failure were assessed in an independent validation cohort of 37 CLAD cases and 37 controls.
Thirty-two candidate genes were associated with CLAD and graft failure, comprising the AI2 score, which clustered into 3 subcomponents. The AI2 score identified CLAD before its onset, in early and late post-CLAD brushes, as well as in the validation cohort (AUC 0.69-0.88). The AI2 score association with CLAD was independent of positive microbiology, CLAD stage, or CLAD subtype. However, transcripts most associated with CLAD evolved over time from CLAD onset. The AI2 score predicted time to graft failure and retransplant-free survival in both cohorts (p ≤ 0.03).
This airway inflammation gene score is associated with CLAD development, graft failure, and death. Future studies defining the molecular heterogeneity of airway inflammation could lead to endotype-targeted therapies.
慢性肺移植物功能障碍(CLAD)限制了肺移植后的生存,但在传统方法诊断之前,大量的肺部损伤已经发生。我们假设小气道基因表达模式可以在肺活量测定诊断之前识别 CLAD 风险,并预测随后的移植物衰竭。
在一个由 45 例 CLAD 病例和 37 例匹配时间的、肺功能稳定>1 年的对照组成的推导队列中,评估了 4 个与排斥相关的转录组中的候选基因与 CLAD 或移植物衰竭的关联。与 CLAD 和移植物衰竭时间无关的候选基因被排除在外,产生了气道炎症 2(AI2)基因集。在一个由 37 例 CLAD 病例和 37 例对照组成的独立验证队列中,评估了 CLAD 和死亡或移植物衰竭的竞争风险的曲线下面积(AUC)。
32 个候选基因与 CLAD 和移植物衰竭有关,包括 AI2 评分,它聚类成 3 个子成分。AI2 评分在 CLAD 发病前、早期和晚期 CLAD 刷检以及验证队列中识别出 CLAD(AUC 0.69-0.88)。AI2 评分与 CLAD 的关联与阳性微生物学、CLAD 分期或 CLAD 亚型无关。然而,与 CLAD 最相关的转录本随着时间的推移从 CLAD 发病开始演变。AI2 评分在两个队列中预测移植物衰竭和再移植无失败的时间(p≤0.03)。
这个气道炎症基因评分与 CLAD 的发展、移植物衰竭和死亡有关。未来定义气道炎症的分子异质性的研究可能会导致针对表型的治疗。